top of page
The Professional Network for Healthcare Experts
FDA approves Novartis Rhapsido as first treatment for symptomatic dermographism
Novartis has secured FDA approval for Rhapsido as the first treatment specifically approved for symptomatic dermographism in adults inadequately controlled by H1 antihistamines.
nuaxia
21 hours ago2 min read
FDA approves Tukysa combination as first-line maintenance therapy for HER2-positive advanced breast cancer
The FDA has approved Pfizer's Tukysa in combination with trastuzumab and pertuzumab as a first-line maintenance treatment for adults with HER2-positive advanced breast cancer.
nuaxia
21 hours ago2 min read
bottom of page